Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies for fibrotic diseases, today announces the initiation of "a partially-blinded ...

A hybrid model combining LM, GA, and BP neural networks improves TCM's diagnostic accuracy for IPF, achieving 81.22% ...

IPF is a chronic lung disease with fibrous tissue formation, leading to respiratory decline and poor prognosis, affecting mainly older adults. Diagnosis is challenging due to its exclusionary nature, ...

IPF is a rare, progressive and fatal lung disease with a median survival of 2-5 years. 1 Pirfenidone is one of only two drugs approved to treat IPF, and for those patients able to tolerate treatment, ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...

FibroGen is focused on developing pamrevlumab, an innovative drug with potential for IPF treatment, which could capture a share of the multi-billion dollar IPF drug market. The PRAISE study showed ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for fibrosis, inflammation, and related diseases. Its lead drug, bexotegrast, is being ...

Please provide your email address to receive an email when new articles are posted on . Saracatinib appeared to be “equal or superior” in stopping fibrotic responses compared with two FDA-approved ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks An announcement from PureTech Health ...

HealthDay News — Recommendations for idiopathic pulmonary fibrosis (IPF) treatment have been updated by an international group of respiratory societies. The updated clinical practice guideline was ...

IPF patient survey provides new insights into disease burden and patient experience one decade after the approval of the first antifibrotics for IPF Clinical abstract reviews the ability of Bayesian ...